MarketLens
Sign Up

Why Did Goldman Sachs Downgrade BioArctic

6 months ago
SHARE THIS ON:

Why Did Goldman Sachs Downgrade BioArctic

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

News•3 weeks ago

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

Goldman Sachs analyst Salveen Richter said large biopharma companies are currently evaluating China-based biotech assets, citing innovation there. The comment signals potential cross-border deal inter...
Stock News•1 months ago

Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®

Canada's Drug Agency issued a final positive recommendation supporting public reimbursement of Leqembi, BioArctic's Alzheimer's drug partnered with Eisai. The decision could expand market access and s...
Stock News•2 months ago

Moderna Drops 7% Despite a Fresh Wolfe Research Upgrade, BioNTech Slips

Moderna fell 7%, reversing part of Tuesday's rally, after a Wolfe Research upgrade failed to hold gains. The pullback reopens valuation questions near a $59 billion market cap, with BioNTech also slip...

Breaking News

View All →

Top Headlines

View More →
Stock News•25 minutes ago

SK Hynix third-quarter profit sharply beats estimates on AI memory boost

Stock News•1 hour ago

History Says the Stock Market's Best 6 Months Start Nov. 1. Here's How Often They've Paid Off Since 1950.

Stock News•2 hours ago

AI Cash Kings: 3 Top Chip Stocks Primed For More Explosive Growth

Stock News•2 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alphabet Inc. of Class Action Lawsuit and Upcoming Deadlines – GOOG

Stock News•2 hours ago

Nvidia's New $3 Billion AI Bet Is on One of Its Own Customers